# NCT05785039 (NCT05785039)

> A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors

No report yet. It can be ordered.

- Drugs tested: izalontamab brengitecan (BL-B01D1)
- Indication: locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05785039
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Conditions: Urinary System Tumor; Solid Tumor
- Interventions: BL-B01D1
- Enrollment: 76
- Primary outcome: Phase IIa: Recommended Phase II Dose (RP2D)
- Primary outcome: Phase IIb: Objective response rate (ORR)

## Indexed commentary on NCT05785039 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05785039
